Rap 2A CRISPR Activation Plasmid (h): sc-403109-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Rap 2A CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Rap 2A CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Rap 2A CRISPR Activation Plasmid (h) and Rap 2A CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the RAP2A transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rap 2A CRISPR Activation Plasmid (h) | sc-403109-ACT | 20 µg | $397.00 |
RAP2A encodes the human small GTPase Rap2A, a Ras superfamily member that cycles between GDP- and GTP-bound states to regulate signal transduction at cellular membranes. Rap2A participates in pathways controlling actin cytoskeleton remodeling, integrin-mediated adhesion, cell polarity, and vesicular trafficking, influencing processes such as migration and neurite outgrowth. Through interactions with effectors that interface with MAPK signaling and Rho family GTPase networks, RAP2A helps coordinate spatial control of proliferation and motility cues. Dysregulated Rap2A signaling has been studied in the context of oncogenic transformation, invasion phenotypes, and neurological and vascular biology where altered adhesion and cytoskeletal dynamics are implicated.
Rap 2A CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous RAP2A expression without altering the underlying DNA sequence.
Rap 2A CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the RAP2A locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the RAP2A transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Rap 2A expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native RAP2A locus and enabling the study of Rap 2A-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Rap 2A pathway restoration in tumor cells with silenced or reduced RAP2A expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.